Media headlines about BioScrip (NASDAQ:BIOS) have been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. BioScrip earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.6514365339188 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Is BioScrip Inc (BIOS) Building Momentum? - FLBC News (flbcnews.com)
- BioScrip Investors’ Attys Win $2.7M In Fees From $11M Deal - Law360 (subscription) (law360.com)
- BioScrip Inc (BIOS)’s Chaikin Flow Showing Positive Signal - Sparta Review (spartareview.com)
- BioScrip, Inc. (BIOS) and State National Companies, Inc. (SNC) Ponder to Gains Active Momentum- Ferro Corporation … - Investing News Update (investingbizz.com)
Several equities research analysts have weighed in on the company. ValuEngine raised BioScrip from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Zacks Investment Research raised BioScrip from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a research note on Wednesday, July 5th. Finally, Barrington Research upped their target price on BioScrip to $3.50 and gave the company an “outperform” rating in a research note on Monday, June 26th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $3.50.
Shares of BioScrip (NASDAQ BIOS) traded down 2.44% during mid-day trading on Friday, hitting $2.80. The company had a trading volume of 551,502 shares. The firm’s market capitalization is $338.75 million. BioScrip has a 52-week low of $0.98 and a 52-week high of $3.43. The firm has a 50-day moving average price of $2.74 and a 200 day moving average price of $1.94.
BioScrip (NASDAQ:BIOS) last posted its quarterly earnings data on Thursday, May 4th. The company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.04. The business had revenue of $217.80 million for the quarter, compared to analysts’ expectations of $230.23 million. During the same quarter last year, the business earned ($0.17) EPS. BioScrip’s revenue was down 8.7% compared to the same quarter last year. Analysts expect that BioScrip will post ($0.38) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece was published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/07/29/bioscrip-nasdaqbios-earns-daily-coverage-optimism-score-of-0-20-updated.html.
About BioScrip
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
